Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.

PubWeight™: 1.22‹?› | Rank: Top 10%

🔗 View Article (PMC 1860092)

Published in Gut on May 18, 2006

Authors

M Sherman1, E M Yoshida, M Deschenes, M Krajden, V G Bain, K Peltekian, F Anderson, K Kaita, S Simonyi, R Balshaw, S S Lee, Canadian Pegasys Study Group

Author Affiliations

1: Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, M5G 2C4 Canada. morris.sherman@uhn.on.ca

Articles citing this

Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06

Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99

Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol (2008) 0.92

S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One (2010) 0.88

De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case. Surg Today (2011) 0.87

Management of chronic hepatitis C treatment failures: role of consensus interferon. Biologics (2009) 0.83

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol (2009) 0.81

Comparison of the abbott 7000 and bayer 340 systems for measurement of hepatitis C virus load. J Clin Microbiol (2007) 0.80

Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin. Dig Dis Sci (2011) 0.80

Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? BMC Infect Dis (2010) 0.79

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open (2017) 0.78

Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy. Int J Med Sci (2012) 0.77

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil. BMC Infect Dis (2012) 0.76

A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res (2016) 0.75

Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. Ann Gastroenterol (2015) 0.75

Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea. Gut Liver (2013) 0.75

The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. Gastroenterol Hepatol (N Y) (2007) 0.75

Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C. Dig Dis Sci (2011) 0.75

Articles cited by this

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet (1998) 9.78

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology (2002) 5.16

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27

World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ (2003) 4.24

EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol (1999) 3.65

Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med (2004) 2.29

Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis (1999) 1.45

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol (2005) 1.12

Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther (2006) 1.07

Treatment of patients with hepatitis C and cirrhosis. Hepatology (2002) 1.02

Retreatment of patients with chronic hepatitis C. Hepatology (2002) 0.87

Retreatment of chronic hepatitis C virus infection. Rev Gastroenterol Disord (2004) 0.84

Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J Viral Hepat (2003) 0.82

Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. BMC Gastroenterol (2003) 0.80

Articles by these authors

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet (1998) 9.78

Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis (1998) 7.51

Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science (1995) 6.03

Synthesis of highly crystalline and monodisperse maghemite nanocrystallites without a size-selection process. J Am Chem Soc (2001) 4.28

Delineating Patterns of Medical Care. Am J Public Health Nations Health (1960) 4.11

Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res (2001) 3.94

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37

Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut (2008) 3.20

Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother (1992) 3.09

Descriptive epidemiology of bronchial reactivity in an adult population: results from a community study. Thorax (1987) 3.06

Carboxylation reactions and photosynthesis of carbon compounds in isolated mesophyll and bundle sheath cells of Digitaria sanguinalis (L.) Scop. Biochem Biophys Res Commun (1970) 3.05

Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect (2006) 3.04

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology (1996) 2.94

Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis. Lancet (2000) 2.90

Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) (2007) 2.81

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA (1999) 2.79

Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest (1993) 2.58

The thalamus as a neuronal oscillator. Brain Res (1984) 2.50

Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology (2007) 2.43

The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42

Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet (1999) 2.42

Obstacles to residents' conducting research and predictors of publication. Acad Med (2001) 2.25

Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene (1999) 2.25

The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine (2013) 2.25

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23

Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis (1988) 2.20

Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene (2000) 2.20

Glassy cell carcinoma of the uterine cervix. Cytologic features and expression of estrogen and progesterone receptors. Acta Cytol (2000) 2.05

A minimal role for selectins in the recruitment of leukocytes into the inflamed liver microvasculature. J Clin Invest (1997) 2.04

Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem (2001) 2.02

Public knowledge, attitudes and behavior on antibiotic use: a telephone survey in Hong Kong. Infection (2008) 2.02

The RNA code and protein synthesis. Cold Spring Harb Symp Quant Biol (1966) 1.96

Success of exchange reamed intramedullary nailing for femoral shaft nonunion or delayed union. J Orthop Trauma (2000) 1.95

Endoscopic ultrasound-guided versus conventional transmural drainage for pancreatic pseudocysts: a prospective randomized trial. Endoscopy (2009) 1.87

Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci (2000) 1.85

Endoscopic removal of biliary self-expandable metallic stents: a prospective study. Endoscopy (2006) 1.83

A model for an estimate in vivo of the ionic basis of presynaptic inhibition: an intracellular analysis of the GABA-induced depolarization in rat dorsal root ganglia. Brain Res (1976) 1.79

Eosinophilic meningitis caused by Angiostrongylus cantonensis: report of 17 cases. Am J Med (2001) 1.76

Evaluation of Roche Amplicor PCR assay for Mycobacterium tuberculosis. J Clin Microbiol (1996) 1.70

Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med (2001) 1.69

Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat (2009) 1.69

Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68

Treatment of acute colonic pseudoobstruction (Ogilvie's syndrome) with cisapride. Gastroenterology (1990) 1.67

Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation (1999) 1.67

REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer (1998) 1.67

Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67

Cardiac abnormalities in liver cirrhosis. West J Med (1989) 1.66

Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy. Cancer (1978) 1.64

Review article: possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol Ther (2007) 1.61

Universal decline in mortality in patients with advanced HIV-1 disease in various demographic subpopulations after the introduction of HAART in Hong Kong, from 1993 to 2002. HIV Med (2006) 1.61

Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med (1994) 1.59

The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Kidney Int (2007) 1.57

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 1.55

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill (2015) 1.50

Sudden infant deaths in sitting devices. Arch Dis Child (2007) 1.50

Occlusive myocardial infarction: investigation of bis-gadolinium mesoporphyrins-enhanced T1-weighted MR imaging in a cat model. Radiology (2001) 1.47

Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology (1996) 1.47

In vitro elution of antibiotic from antibiotic-impregnated biodegradable calcium alginate wound dressing. J Trauma (1999) 1.47

Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat (2005) 1.46

Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol (2001) 1.46

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45

Initial experiences with a multidisciplinary approach to decreasing the length of hospital stay for patients undergoing unilateral mastectomy. Eur J Surg Oncol (2011) 1.45

Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut (2008) 1.45

Differences in clinical and laboratory diagnostic characteristics of penicilliosis marneffei in human immunodeficiency virus (HIV)- and non-HIV-infected patients. J Clin Microbiol (2001) 1.44

Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol (2001) 1.44

Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology (1993) 1.43

Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int (2006) 1.42

Comparison of six commercial techniques in the measurement of microalbuminuria in diabetic patients. Diabetes Care (1993) 1.42

Patterns of Medical Care: A Hospital's Outpatients. Am J Public Health Nations Health (1960) 1.42

Risk factors for recurrence of primary bile duct stones after endoscopic biliary sphincterotomy. Gastrointest Endosc (2001) 1.42

Extracorporeal circulation combined with hypothermia and hemodilution technique. Yonsei Med J (1963) 1.40

Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl (2001) 1.40

Primary biliary cirrhosis and inflammatory bowel disease. Am J Gastroenterol (1993) 1.39

Binary phase spatial modulation using photoinduced anisotropy in amorphous As(2)S(3) thin film. Appl Opt (1995) 1.39

Human adenovirus early region 4 open reading frame 1 genes encode growth-transforming proteins that may be distantly related to dUTP pyrophosphatase enzymes. J Virol (1997) 1.39

Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol (1998) 1.39

Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol (1998) 1.38

Augmentative plate fixation for the management of femoral nonunion after intramedullary nailing. J Trauma (1997) 1.38

Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant (2004) 1.37

Putaminal petechial haemorrhage as the cause of chorea: a neuroimaging study. J Neurol Neurosurg Psychiatry (1997) 1.36

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer (2009) 1.36

Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem (2001) 1.34

Lymphocyte subpopulation reference ranges for monitoring human immunodeficiency virus-infected Chinese adults. Clin Diagn Lab Immunol (1996) 1.32

Choledochal cyst. A report of nine cases and review of the literature. Arch Surg (1969) 1.31

Mechanisms of steroid oxidation by microorganisms. XII. Metabolism of hexahydroindanpropionic acid derivatives. Biochemistry (1967) 1.30

No association between hepatitis C and B-cell lymphoma. Hepatology (1999) 1.28

A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol (2001) 1.28

Mechanisms of steroid oxidation by microorganisms. 8. 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione, an intermediate in the microbiological degradation of ring A of androst-4-ene-3,17-dione. J Biol Chem (1966) 1.27

Phylogenetic relationships of Asian and European pig breeds determined by mitochondrial DNA D-loop sequence polymorphism. Anim Genet (2002) 1.27

Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology (1999) 1.26

Clinical characteristics of emphysematous pyelonephritis. J Microbiol Immunol Infect (2001) 1.26

Analysis of percutaneous transhepatic cholangioscopy-related complications and the risk factors for those complications. Endoscopy (2007) 1.25

Inflammatory pseudotumors of the lung. Surg Gynecol Obstet (1983) 1.25

The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer (1997) 1.24